Literature DB >> 21946334

Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease.

Teresa Botta-Orfila1, Eduard Tolosa, Ellen Gelpi, Alex Sànchez-Pla, Maria-José Martí, Francesc Valldeoriola, Manel Fernández, Francesc Carmona, Mario Ezquerra.   

Abstract

LRRK2 mutations are the most common genetic cause of Parkinson's disease (PD). We performed a whole-genome RNA profiling of putamen tissue from idiopathic PD (IPD), LRRK2-associated PD (G2019S mutation), neurologically healthy controls and one asymptomatic LRRK2 mutation carrier, by using the Genechip Human Exon 1.0-ST Array. The differentially expressed genes found in IPD revealed an alteration of biological pathways related to long-term potentiation (LTP), GABA receptor signalling, and calcium signalling pathways, among others. These pathways are mainly related with cell signalling cascades and synaptic plasticity processes. They were also altered in the asymptomatic LRRK2 mutation carrier but not in the LRRK2-associated PD group. The expression changes seen in IPD might be attributed to an adaptive consequence of a dysfunction in the dopamine transmission. The lack of these altered molecular pathways in LRRK2-associated PD patients suggests that these cases could show a different molecular response to dopamine transmission impairment.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21946334     DOI: 10.1016/j.nbd.2011.08.033

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  16 in total

1.  Network and Pathway-Based Analyses of Genes Associated with Parkinson's Disease.

Authors:  Yanshi Hu; Zhenhua Pan; Ying Hu; Lei Zhang; Ju Wang
Journal:  Mol Neurobiol       Date:  2016-06-27       Impact factor: 5.590

2.  α-Synuclein overexpression represses 14-3-3θ transcription.

Authors:  Huiping Ding; Naomi S Fineberg; Michelle Gray; Talene A Yacoubian
Journal:  J Mol Neurosci       Date:  2013-08-04       Impact factor: 3.444

3.  Dopamine neuron-specific LRRK2 G2019S effects on gene expression revealed by translatome profiling.

Authors:  Judit Pallos; Sophia Jeng; Shannon McWeeney; Ian Martin
Journal:  Neurobiol Dis       Date:  2021-05-11       Impact factor: 5.996

4.  LRRK2 in Transcription and Translation Regulation: Relevance for Parkinson's Disease.

Authors:  Véronique Dorval; Sébastien S Hébert
Journal:  Front Neurol       Date:  2012-02-10       Impact factor: 4.003

Review 5.  Gene expression in the Parkinson's disease brain.

Authors:  Patrick A Lewis; Mark R Cookson
Journal:  Brain Res Bull       Date:  2011-12-03       Impact factor: 4.077

6.  Evidence for Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson's Disease.

Authors:  Anke A Dijkstra; Angela Ingrassia; Renee X de Menezes; Ronald E van Kesteren; Annemieke J M Rozemuller; Peter Heutink; Wilma D J van de Berg
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

7.  Validity of the MPTP-Treated Mouse as a Model for Parkinson's Disease.

Authors:  Cornelius J H M Klemann; Gerard J M Martens; Geert Poelmans; Jasper E Visser
Journal:  Mol Neurobiol       Date:  2015-02-13       Impact factor: 5.590

Review 8.  Gene expression profiling in human neurodegenerative disease.

Authors:  Johnathan Cooper-Knock; Janine Kirby; Laura Ferraiuolo; Paul R Heath; Magnus Rattray; Pamela J Shaw
Journal:  Nat Rev Neurol       Date:  2012-08-14       Impact factor: 42.937

9.  A genome-wide association study of a sustained pattern of antidepressant response.

Authors:  Aimee M Hunter; Andrew F Leuchter; Robert A Power; Bengt Muthén; Patrick J McGrath; Cathryn M Lewis; Ian A Cook; Holly A Garriock; Peter McGuffin; Rudolf Uher; Steven P Hamilton
Journal:  J Psychiatr Res       Date:  2013-05-30       Impact factor: 4.791

10.  Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease.

Authors:  Arash Hossein-Nezhad; Roya Pedram Fatemi; Rili Ahmad; Elaine R Peskind; Cyrus P Zabetian; Shu-Ching Hu; Min Shi; Claes Wahlestedt; Jing Zhang; Mohammad Ali Faghihi
Journal:  J Parkinsons Dis       Date:  2016       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.